AU1775300A - Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system - Google Patents

Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system Download PDF

Info

Publication number
AU1775300A
AU1775300A AU17753/00A AU1775300A AU1775300A AU 1775300 A AU1775300 A AU 1775300A AU 17753/00 A AU17753/00 A AU 17753/00A AU 1775300 A AU1775300 A AU 1775300A AU 1775300 A AU1775300 A AU 1775300A
Authority
AU
Australia
Prior art keywords
azabicyclo
ethyl
exo
fluorophenyl
heptan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17753/00A
Other languages
English (en)
Inventor
Gerhard Gross
Rainer Munschauer
Gerd Steiner
Hans-Jurgen Teschendorf
Martin Traut
Liliane Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU1775300A publication Critical patent/AU1775300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU17753/00A 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system Abandoned AU1775300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19854147 1998-11-24
DE19854147A DE19854147A1 (de) 1998-11-24 1998-11-24 Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Verwendung bei der Bekämpfung der Cocainsucht
PCT/EP1999/008734 WO2000030639A1 (de) 1998-11-24 1999-11-12 Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems

Publications (1)

Publication Number Publication Date
AU1775300A true AU1775300A (en) 2000-06-13

Family

ID=7888824

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17753/00A Abandoned AU1775300A (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system

Country Status (21)

Country Link
EP (1) EP1133293A1 (zh)
JP (1) JP2002530333A (zh)
KR (1) KR20010080535A (zh)
CN (1) CN1328455A (zh)
AR (1) AR021502A1 (zh)
AU (1) AU1775300A (zh)
BG (1) BG105549A (zh)
BR (1) BR9915589A (zh)
CA (1) CA2352526A1 (zh)
CZ (1) CZ20011796A3 (zh)
DE (1) DE19854147A1 (zh)
HK (1) HK1040933A1 (zh)
HR (1) HRP20010472A2 (zh)
HU (1) HUP0104416A3 (zh)
IL (1) IL143181A0 (zh)
NO (1) NO20012538L (zh)
PL (1) PL348758A1 (zh)
SK (1) SK7112001A3 (zh)
TR (1) TR200101476T2 (zh)
WO (1) WO2000030639A1 (zh)
ZA (1) ZA200103976B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1836183A2 (en) 2004-12-13 2007-09-26 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
GB0812310D0 (en) 2008-07-03 2008-08-13 Syngenta Ltd Novel herbicides
WO2014111837A1 (en) * 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004311A1 (en) * 1987-11-12 1989-05-18 American Home Products Corporation Polycyclicamines with psychotropic activity
DE4427648A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
DE4427647A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
WO2000030639A1 (de) 2000-06-02
CZ20011796A3 (cs) 2002-05-15
ZA200103976B (en) 2002-05-16
DE19854147A1 (de) 2000-05-25
BR9915589A (pt) 2001-08-07
HK1040933A1 (zh) 2002-06-28
JP2002530333A (ja) 2002-09-17
PL348758A1 (en) 2002-06-03
HUP0104416A2 (hu) 2002-04-29
SK7112001A3 (en) 2001-12-03
BG105549A (en) 2001-12-29
EP1133293A1 (de) 2001-09-19
IL143181A0 (en) 2002-04-21
HUP0104416A3 (en) 2002-11-28
NO20012538D0 (no) 2001-05-23
KR20010080535A (ko) 2001-08-22
TR200101476T2 (tr) 2001-10-22
AR021502A1 (es) 2002-07-24
HRP20010472A2 (en) 2003-04-30
CA2352526A1 (en) 2000-06-02
CN1328455A (zh) 2001-12-26
NO20012538L (no) 2001-07-04

Similar Documents

Publication Publication Date Title
AU2001282734B2 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
CN101208093A (zh) 吡唑-嘧啶衍生物在治疗疼痛中的用途
US20090209536A1 (en) Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US20100069375A1 (en) Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses
KR20160005341A (ko) Ampk 활성인자 및 세로토닌성 제제를 포함하는 약학 조성물 및 이의 사용 방법
ES2327845T3 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su uso como moduladores de 5-ht-6.
AU2001282734A1 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
JP2010508345A (ja) 鎮痛活性を有し、そのため疼痛の治療または予防において有用であるピラゾリル誘導体
US5475105A (en) N-substituted azabicycloheptane derivatives
AU2006292256B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
KR100397525B1 (ko) 뇌혈관 장해에 수반되는 정신증후치료제
AU1775300A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
US6818639B2 (en) Pharmaceutical combination formulation and method of treatment with the combination
US20150141410A1 (en) GPR17 Receptor Modulators
MXPA01005104A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
US20240018125A1 (en) Cyclic isothiourea derivatives as cxcr4 modulators
JP3274454B2 (ja) 新規なシアノインドールセロトニン再取り込み阻害化合物、その調製方法及びそれらを含む医薬組成物
Slassi et al. Novel serotonergic and non-serotonergic migraine headache therapies
Behan et al. 5ht 2C receptor modulator compositions
CN101547927A (zh) 8-磺酰基-1，3，4，8-四氢-2h-[1，4]氧氮杂并[6，7-e]吲哚衍生物和它们作为5-ht6受体配体的应用
EA000793B1 (ru) Способ лечения бессонницы
WO2013029043A1 (en) Selective kinase inhibitors

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted